White paper
From lab to label : Aligning trademark strategy with regulatory approval
A trademark is more than a branding decision in the pharmaceutical industry; it plays a central role in regulatory approval, patient safety and commercial success.
Drug names must differentiate products in the market, but they also introduce unique risks. Look alike and sound alike names can contribute to medication errors, delay market entry and trigger costly rebranding if not carefully managed.
Download this white paper to learn:
- The nuances that make pharmaceutical naming uniquely challenging
- How regulatory review really works across major global authorities
- Common pitfalls that lead to delays, refusals, and rebranding
- Practical strategies to strengthen trademark and naming decisions early
This white paper was developed with the support of experienced industry practitioners who offer deep, first hand insight into pharmaceutical naming and regulatory practice.
Maury M. Tepper III, Partner at Tepper & Eyster PLLC, and Dierdre Clark, IP Counsel, Legal Brand Protection at Novartis, contributed their perspectives to ensure the analysis reflects real world challenges and the evolving expectations of regulators and IP professionals around the world.
Their expertise, combined with the global view of trademark and regulatory workflows at Clarivate, has shaped a resource designed to be both practical and actionable.
Download the white paper and make more confident pharmaceutical naming decisions.
